Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial Meeting Abstract
| Authors: | Geyer, M. B.; Burke, P. W.; King, A. C.; Mauro, M. J.; Tallman, M. S.; Levine, R. L.; Sherr, C. J.; Douer, D.; Park, J. H. |
| Abstract Title: | Ruxolitinib in combination with dasatinib and dexamethasone is an active and well-tolerated chemotherapy-sparing oral induction regimen for adults with Philadelphia chromosome-positive ALL: Results of a phase I trial |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837607298 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-110537 |
| Notes: | Meeting Abstract: 2692 -- Source: Wos |
Altmetric
Citation Impact
